MedWatch

Astellas shakes structure of R&D division

Japanese pharmaceutical company Astellas plans to implement a more flat structure in its research and development division in pursuit of developing new, innovative medicaments.

Astella's office in Denmark. | Photo: Astellas / PR

Japanese pharmaceutical firm Astellas moves to reform its research and development unit in the aim of developing competitive products, the company writes in a press statement.

The changes, set to enter force from Oct. 1 this year, are meant to facilitate a more agile R&D division as well as to maximize synergies between the company's range of divisions.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs